Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity

Volumn 2, Issue , 2009, Pages 61-71

  Valensi, Paul ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

BIAsp 30; Biphasic insulin aspart; Premix; Type 1 diabetes; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIPHASIC INSULIN; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE;

ADD ON THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INFESTATION; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MONOTHERAPY; MORNING DOSAGE; NEUROLOGIC DISEASE; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 77953451093     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/dmsott.s3408     Document Type: Review

References (67)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
2. DCCT/EDIC: Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287(19):2563-2569.
3. Bjarnegård N, Arnqvist HJ, Lindström T, Jonasson L, Jönsson A, Länne T. Long-term hyperglycemia impairs vascular smooth muscle cell function in women with type 1 diabetes mellitus. Diab Vasc Dis Res. 2009;6(1):25-31.
4. Potenza MA, Gagliardi S, Nacci C, Carratu' MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem. 2009;16(1):94-112.
5. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31(3):596-615.
6. Holmes J, McGill S, Kind P, Bottomley J, Gillam S, Murphy M. Health-related quality of life in type 2 diabetes (TARDIS-2). Value Health. 2000;3(Suppl 1):47-51.
7. Valensi P, Benroubi M, Borzi V, et al; IMPROVE Study Group Expert Panel. The IMPROVE study - a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts. Int J Clin Pract. 2008;62(11):1809-1819.
8. Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther. 2007;29 Spec No:1236-1253.
9. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005. http://www.idf.org/webdata/ docs/IDF%20GGT2D.pdf
10. Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258): 405-412.
11. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001 Jul 21;358(9277):221-229.
12. Jeitler K, Horvath K, Berghold A, et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia. 2008;51(6):941-951.
13. Schiaffini R, Patera PI, Bizzarri C, Ciampalini P, Cappa M. Basal insulin supplementation in Type 1 diabetic children: a long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin. J Endocrinol Invest. 2007;30(7):572-577.
14. Renard E. Intensive insulin therapy today: 'basal-bolus' using multiple daily injections or CSII? Diabetes Metab. 2005;31(4 Pt 2):4S40-4S44.
15. Harris MI. Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). Clin Invest Med. 1995;18(4): 231-239.
16. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998;19:491-503.
17. Mason CC, Hanson RL, Knowler WC. Progression to type 2 diabetes characterized by moderate then rapid glucose increases. Diabetes. 2007;56:2054-2061.
18. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Reviews. 1999;7:139-153.
19. UK. Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44(11):1249-1258.
20. Steyn NP, Lambert EV, Tabana H. Nutrition interventions for the prevention of type 2 diabetes. Proc Nutr Soc. 2009;68(1):55-70.
21. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012.
22. Wright A, Burden ACF, Paisey RB, et al; for the UK. Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330-336.
23. Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab. 2007;9(5):630-639.
24. Brange J, Volund A. Insulin analogs with improved pharmacokinetic profiles. Advanced Drug Delivery Reviews. 1999;35:307-335.
25. Bolli GB. Physiological insulin replacement in type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2):S317-S332.
26. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care. 1997;20(10):1612-1614.
27. Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol. 2000;56:399-403.
28. McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther. 2002;24(4):530-539.
29. Hermansen K, Colombo M, Storgaard H, ØStergaard A, Kølendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care. 2002;25(5):883-888.
30. Luzio S, Dunseath G, Peter R, Pauvaday V, Owens DR. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia. 2006;49(6):1163-1168.
31. Mortensen H, Kocova M, Teng LY, Keiding J, Bruckner I, Philotheou A. Biphasic insulin aspart vs human insulin in adolescents with type 1 diabetes on multiple daily insulin injections. Pediatr Diabetes. 2006;7(1):4-10.
32. Chen JW, Lauritzen T, Bojesen A, Christiansen JS. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basalbolus human insulin treatment in patients with type 1 diabetes. Diabetes Obes Metab. 2006;8(6):682-689.
33. Hermansen K, Vaaler S, Madsbad S, et al. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. Metabolism. 2002;51(7):896-900.
34. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients. Diabet Med. 2002;19(5):393-399.
35. Raskin P, Allen E, Hollander P, et al. INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260-265.
36. Raskin PR, Hollander PA, Lewin A, Gabbay RA, Bode B, Garber AJ; on behalf of the INITIATE Study Group. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med. 2007;18(1):56-62.
37. Raskin P, Matfin G, Schwartz SL, et al. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts). Diabetes Obes Metab. 2009;11(1):27-32.
38. Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114(9):527-532.
39. Velojic-Golubovic M, Mikic D, Pesic M, Dimic D, Radenkovic S, Antic S. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with type 2 diabetes. J Endocrinol Invest. 2009;32(1):23-27.
40. Kilo C, Mezitis N, Jain R, Mersey J, McGill J, Raskin P. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications. 2003;17(6):307-313.
41. Kabadi UM, Kabadi M. Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes. Diabetes Res Clin Pract. 2006;72(3):265-270.
42. Bebakar WM, Chow CC, Kadir KA, Suwanwalaikorn S, Vaz JA, Bech OM; BIAsp-3021 study group. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(5):724-732.
43. Home PD, Bailey CJ, Donaldson J, Chen H, Stewart MW. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes. Diabet Med. 2007;24(6):618-625.
44. Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B; PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab. 2009;11(1):45-52.
45. Ushakova O, Sokolovskaya V, Morozova A, et al. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in Russia. Clin Ther. 2007;29(11): 2374-2384.
46. Kvapil M, Swatko A, Hilberg C, Shestakova M. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes Obes Metab. 2006;8(1):39-48.
47. Yang W, Ji Q, Zhu D, et al. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. Diabetes Care. 2008;31(5):852-856.
48. Raz I, Stranks S, Filipczak R, et al. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clin Ther. 2005;27(9):1432-1443.
49. Boehm BO, Vaz JA, Brøndsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med. 2004;15(8):496-502.
50. Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab. 2006;8(1):58-66.
51. McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care. 2007;30(5):1044-1048.
52. Barnett AH. Summarising the use of thiazolidinediones with insulin. Br J Diab Vasc Dis. 2007;7:75-80.
53. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care. 2009;32(Suppl 1):S13-S61.
54. Korytkowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25(11):2836-2848.
55. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005; 27(Suppl B):S89-S100.
56. Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther. 2008;10(4):247-256.
57. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care. 2002;25(5):876-882.
58. Chen JW, Frystyk J, Lauritzen T, Christiansen JS. Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes. Eur J Endocrinol. 2005;153(6):907-913.
59. Breum L, Almdal T, Eiken P, Lund P, Christiansen E; on behalf of the Danish BIAsp Study Group. Initiating or Switching to Biphasic Insulin Aspart 30/70 Therapy in Subjects with Type 2 Diabetes Mellitus. An Observational Study. Rev Diabet Stud. 2008;5(3):154-162.
60. Valensi P, Benroubi M, Borzi V, et al; on behalf of the IMPROVE™ Study Group Expert Panel. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30?70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study. Int J Clin Pract. 2009;63(3):522-531.
61. Shah S, Benroubi M, Borzi V, et al; on behalf of the IMPROVE™ Study Group Expert Panel. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study. Int J Clin Pract. 2009;63(4):574-582.
62. Khutsoane D, Sharma SK, Almustafa M, et al; PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10(3):212-222.
63. Jang HC, Guler S, Shestakova M; PRESENT Study Group. When glycemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. Int J Clin Pract. 2008;62(7):1013-1018.
64. Shestakova M, Sharma SK, Almustafa M, et al. Transferring type 2 diabetes patients with uncontrolled glycemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr Med Res Opin. 2007;23(12):3209-3214.
65. Sharma SK, Al-Mustafa M, Oh SJ, et al. Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. Curr Med Res Opin. 2008;24(3):645-652.
66. Ligthelm RJ, Borzì V, Gumprecht J, Kawamori R, Wenying Y, Valensi P. Importance of observational studies in clinical practice. Clin Ther. 2007;29 Spec no:1284-1292.
67. Shah S, Ørskov C, Kawamori R. Switching to NovoMix® 30 (BIAsp 30) improves glycemic control in patients with type 2 diabetes previously treated with insulin: subgroup analysis from the IMPROVE™ study. Diabetes. 2008;57(Suppl 1):A592.